MgShell is developing a magnesium-based drug delivery platform that allows for a single intraocular injection to release therapeutic doses over time, significantly reducing the need for frequent intravitreal injections in patients with age-related macular degeneration. This technology enhances patient adherence to treatment and lowers overall healthcare costs associated with chronic ocular diseases.
Funding
$544.7K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with retinal diseases, such as age-related macular degeneration, often require frequent intravitreal injections to maintain therapeutic drug levels, leading to poor patient compliance and increased healthcare costs. Current drug delivery methods do not provide sustained release, necessitating repeated clinical visits and invasive procedures.
Solution
MgShell is developing a magnesium-based drug delivery platform designed for sustained intraocular drug release following a single injection. The platform utilizes biocompatible magnesium to create a controlled-release mechanism within the eye, reducing the frequency of intravitreal injections needed for treating retinal diseases. This approach aims to improve patient adherence to treatment regimens by minimizing the burden of frequent clinic visits and injections. By providing a more consistent therapeutic effect, MgShell's technology has the potential to lower overall healthcare costs associated with managing chronic ocular conditions. The platform is designed to be adaptable for various drugs and retinal diseases, offering a versatile solution for long-term ophthalmic care.
Target Audience
The primary target audience includes ophthalmologists and retinal specialists treating patients with chronic retinal diseases, as well as patients requiring long-term management of conditions like age-related macular degeneration.
Features
- Magnesium-based implant for controlled drug release in the vitreous cavity
- Biocompatible and biodegradable material composition
- Customizable drug elution profiles for tailored therapeutic needs
- Minimally invasive injection procedure
- Potential for reduced injection frequency compared to standard treatments